Protagonist Therapeutics Inc (PTGX)
41.04
-1.63
(-3.82%)
USD |
NASDAQ |
Nov 14, 16:00
41.04
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Cash from Financing (Quarterly): 12.05M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 12.05M |
| June 30, 2024 | 2.572M |
| March 31, 2024 | 7.199M |
| December 31, 2023 | 0.527M |
| September 30, 2023 | 35.32M |
| June 30, 2023 | 108.17M |
| March 31, 2023 | 26.46M |
| December 31, 2022 | 0.553M |
| September 30, 2022 | 0.68M |
| June 30, 2022 | 0.68M |
| March 31, 2022 | 16.92M |
| December 31, 2021 | 2.173M |
| September 30, 2021 | 1.381M |
| June 30, 2021 | 125.39M |
| March 31, 2021 | 0.979M |
| December 31, 2020 | 126.98M |
| September 30, 2020 | 7.669M |
| June 30, 2020 | 112.58M |
| March 31, 2020 | 0.399M |
| December 31, 2019 | 9.779M |
| Date | Value |
|---|---|
| September 30, 2019 | 25.24M |
| June 30, 2019 | 10.63M |
| March 31, 2019 | 0.39M |
| December 31, 2018 | 0.479M |
| September 30, 2018 | 23.03M |
| June 30, 2018 | 0.074M |
| March 31, 2018 | 0.53M |
| December 31, 2017 | 65.06M |
| September 30, 2017 | 0.031M |
| June 30, 2017 | 0.087M |
| March 31, 2017 | 0.374M |
| December 31, 2016 | -0.852M |
| September 30, 2016 | 85.28M |
| June 30, 2016 | -0.75M |
| March 31, 2016 | 22.63M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 17.36M |
| June 30, 2015 | 0.055M |
| March 31, 2015 | 0.002M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.399M
Minimum
Mar 2020
126.98M
Maximum
Dec 2020
29.92M
Average
7.434M
Median
Cash from Financing (Quarterly) Benchmarks
| Johnson & Johnson | -9.882B |
| Assembly Biosciences Inc | 12.45M |
| Precision BioSciences Inc | 3.733M |
| Entrada Therapeutics Inc | -0.011M |
| NovaBay Pharmaceuticals Inc | 2.089M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.86M |
| Cash from Investing (Quarterly) | -208.71M |
| Free Cash Flow | 229.23M |
| Free Cash Flow Per Share (Quarterly) | -0.4636 |
| Free Cash Flow to Equity (Quarterly) | -28.64M |
| Free Cash Flow to Firm (Quarterly) | -28.64M |
| Free Cash Flow Yield | 9.04% |